RELAY: Repeated Magnetic Resonance Imaging Examinations to Analyze and Assess Your Cancer: A Prospective Study on the Use of Serial Magnetic Resonance Imaging in the Assessment of Changes During Treatment With Radiation Therapy
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 149
- 试验地点
- 4
- 主要终点
- Feasibility of acquiring serial MRI scans on an MRI simulator during treatment with radiation therapy
研究概览
简要总结
This is a phase 1 study to determine the feasibility and utility of using serial magnetic resonance imaging (MRI) to assess treatment response during and after radiation therapy (standard of care cancer treatment) for participants with advanced esophageal cancer, glioblastoma, prostate cancer, vulvar cancer or pediatric glioma.
The research study procedures include three MRI scans (one before, one during, and one after standard of care cancer radiation therapy) for participants with advanced esophageal cancer, glioblastoma, prostate cancer, vulvar cancer or pediatric glioma.
The research study procedures include:
- Screening for eligibility
- Three MRI scans
详细描述
This is a phase 1, non-randomized, open-label study evaluating feasibility of serial MRI, with an option for an expansion cohort. The optional expansion cohort is a prospective imaging registry evaluating imaging biomarkers as predictors of disease control with standard of care treatment.
This research study is a feasibility study, meaning that it is the first time that investigators at this institution are examining the process of getting multiple MRIs during radiation treatment.
The U.S. Food and Drug Administration (FDA) has cleared this MRI scanner for use.
Participants who fulfill eligibility criteria will be entered into the trial.
The research study procedures include screening for eligibility, and three MRI scans. MRI imaging will be performed as per disease site standards.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Other
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants must have a confirmed malignancy requiring radiation therapy.
- •Age: 18 years or older except where otherwise specified in subprotocol.
- •ECOG performance status ≤2 (Karnofsky ≥60%)
- •Ability to understand and the willingness to sign a written informed consent document.
- •Any further criteria listed in the specific disease site subprotocol.
- •(Esophageal cohort) Patients must be considered appropriate candidates for neoadjuvant chemoradiation therapy followed by esophagectomy. Patients must have an endoscopic ultrasound done or scheduled to be done at the baseline visit.
- •(Glioblastoma cohort) Patients with a histologically confirmed newly diagnosed intracranial glioblastoma or gliosarcoma who will be undergoing radiation therapy as part of clinical care.
- •(Prostate cohort) Patients with localized prostate cancer who are planning to receive androgen deprivation therapy and definitive radiation therapy.
- •(Vulvar cohort) Patients with biopsy-proven locally advanced vulvar cancer for which definitive radiotherapy is planned.
- •(Pediatric glioma cohort) Patients age 18 or under (patients 18-30 years old are also eligible if the physician determines that based on genetics, the tumor biology is consistent with pediatric high grade glioma). Patients with a histologically confirmed newly diagnosed high-grade glioma (WHO grade III or IV) who will be undergoing radiation therapy as part of clinical care. Patients with DIPG are only eligible if biopsy-confirmed high grade DIPG is present. Ability to understand and/or willingness of their parent or legally authorized representative to sign a written informed consent document.
- •(Sarcoma cohort) Patients with a histologically confirmed newly diagnosed high-grade glioma (WHO grade III or IV) who will be undergoing radiation therapy as part of clinical care.
排除标准
- •Disease-specific exclusion criteria will be specified in a subprotocol.
- •For MRI involving contrast, history of allergic reactions attributed to gadolinium-based IV contrast. If patient will not receive contrast, this is not applicable and kidney function will not affect eligibility.
- •Inability to undergo magnetic resonance imaging (MRI).
研究组 & 干预措施
Glioblastoma Expansion Cohort Serial MR Imaging Registry
The research study procedures include:
- Screening for eligibility
- Three MRI scans prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards.
干预措施: MRI IMAGING (Diagnostic Test)
Prostate Cancer Cohort
The research study procedures include:
- Screening for eligibility
- Three MRI scans prior to start of androgen deprivation therapy, prior to the start of radiation treatment, and after radiation treatment). Imaging with MRI will be performed as per disease site standards.
- Genomic testing of biopsy sample
干预措施: MRI IMAGING (Diagnostic Test)
Prostate Cancer Expansion Cohort Serial MR Imaging Registry
The research study procedures include:
- Screening for eligibility
- Three MRI scans prior to start of androgen deprivation therapy, prior to the start of radiation treatment, and after radiation treatment). Imaging with MRI will be performed as per disease site standards.
- Genomic testing of biopsy sample
干预措施: MRI IMAGING (Diagnostic Test)
Vulvar Cancer Cohort
The research study procedures include:
- Screening for eligibility
- Three MRI scans prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards.
干预措施: MRI IMAGING (Diagnostic Test)
Pediatric Glioma Cohort
The research study procedures include:
- Screening for eligibility
- Three MRI scans prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards.
干预措施: MRI IMAGING (Diagnostic Test)
Sarcoma Cohort
The research study procedures include: • Screening for eligibility • Three MRI scans prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards.
干预措施: MRI IMAGING (Diagnostic Test)
Esophageal Cohort
The research study procedures include:
- Screening for eligibility
- Three MRI scans (prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards.
干预措施: MRI IMAGING (Diagnostic Test)
Glioblastoma Cohort
The research study procedures include:
- Screening for eligibility
- Three MRI scans prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards.
干预措施: MRI IMAGING (Diagnostic Test)
结局指标
主要结局
Feasibility of acquiring serial MRI scans on an MRI simulator during treatment with radiation therapy
时间窗: 1 year
90% lower confidence limit (LCL) on the true feasibility rate. Feasibility is defined as successfully enrolling patients, acquiring MRI data at all timepoints, identifying the target on MRI data obtained at all timepoints, and processing MRI data at all timepoints to yield pre-specified MRI-derived measurements.
Ability to measure disease control (for imaging registry expansion cohort)
时间窗: 2 years
Validating a previously developed predictive model to identify the most likely area of recurrence using MRI-based features.
次要结局
- Dosimetric change(1 year)
研究者
Jonathan Leeman, MD
Principal Investigator
Dana-Farber Cancer Institute